gliomes

This single-center retrospective study investigated the prognostic impact of MGMT promoter methylation and TERT promoter mutations in 54 patients with WHO grade 4 glioblastoma. The findings indicate that MGMT methylation is independently associated with improved overall survival, whereas TERT mutations predict worse survival. Adjuvant chemoradiotherapy was also confirmed to improve outcomes. A combined stratification using both biomarkers allows for the identification of four distinct prognostic subgroups, with MGMT-methylated/TERT-wild-type patients exhibiting the longest survival.

This study identified invasion/metastasis-related differentially methylated genes (DMGs) with prognostic relevance in diffuse gliomas. A risk model was constructed using two marker genes, ERRFI1 and MYO1G, demonstrating robust predictive performance in both training and independent validation cohorts. Patients classified as high-risk exhibited worse overall survival and altered immune infiltration. In vitro functional validation showed that knockdown of ERRFI1 or MYO1G inhibited glioma cell proliferation, invasion, and migration, with potential involvement of the EGFR/MAPK/ERK pathway.